Posts tagged pivotal study
Profound Medical completes enrollment in TACT pivotal trial

Profound Medical (OTCQX:PRFMF; TSXV:PRN) has completed patient enrollment in the TACT pivotal study designed to further evaluate safety and efficacy of its TULSA-PRO medical device to ablate prostate tissue in patients with localized, organ-confined prostate cancer.

Read More
HCW starts ZIOPHARM at buy

H.C. Wainwright initiated coverage of ZIOPHARM Oncology (NASDAQ:ZIOP) with a “buy” rating and $9.50 price target. The stock closed at $5.85 on May 31.

Read More
Leerink assumes coverage of Edge Therapeutics at OP

Leerink analyst Paul Mattels is assuming coverage of Edge Therapeutics (NASDAQ:EDGE) with an “outperform” rating and $21 price target. The stock closed at $9.40 on March 2.

Read More
Roth cuts GenVec price target to $2

Roth Capital Partners lowered its price target for “buy-rated” GenVec (NASDAQ:GNVC) to $2 from $8, even though the FDA lifted the clinical hold on CGF166, being run worldwide by partner Novartis. The stock closed at 60 cents on Friday.

“This is an important milestone for the GenVec as CGF166 could be the first gene therapy approved for hearing loss,” writes analyst Joseph Pantginis. New patients will be entering cohort 4 in the dose escalation phase and the study is still expected to be complete in 2017.

Read More
Roth adjusts DelMar Pharma price target to $12

Roth Capital Partners has adjusted its price target for DelMar Pharmaceuticals (OTCQX:DMPID) to $12 from $3 after the company’s 1-for-4 reverse stock split. The stock closed at $5.41 on Friday.

Analyst Joseph Pantginis writes that the company’s net equity and operating funds are now sufficient to meet the goal of up listing to a senior exchange, either NASDAQ or NYSE-MKT, shortly.

Read More